{
    "clinical_study": {
        "@rank": "20226", 
        "brief_summary": {
            "textblock": "The purpose of this study is to see if it is safe and effective to give MKC-442 plus\n      stavudine (d4T) plus didanosine (ddI) plus hydroxyurea."
        }, 
        "brief_title": "A Study of MKC-442 in Combination With Other Anti-HIV Drugs", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients are randomized to receive either MKC-442 or placebo, along with stavudine(d4T),\n      didanosine(ddI), and hydroxyurea. Patients will be treated and followed for 48 weeks."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Concurrent Medication:\n\n        Allowed:\n\n        - Based on medical history, medical condition, prior use of antiretroviral drugs, and\n        genotypic analysis of the predominant strain of HIV-1 isolated from the plasma,\n        administration of a combination of two or more available antiretroviral agents by\n        prescription may be given with MKC-442.\n\n        Patient must have:\n\n          -  HIV infection with HIV-1 RNA greater than or equal to 5,000 by Roche Amplicor method\n             within 30 days of entry.\n\n          -  A failed protease inhibitor-containing regimen.\n\n          -  Negative serum beta human chorionic gonadotropin test within 30 days of entry.\n\n        Prior Medication:\n\n        Allowed:\n\n          -  Prior nucleoside reverse transcriptase and protease inhibitors.\n\n          -  Cytotoxic chemotherapy more than 30 days prior to entry.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following symptoms or conditions are excluded:\n\n          -  Malabsorption or severe chronic diarrhea within 30 days prior to entry, or inability\n             to consume adequate oral intake because of chronic nausea, emesis, or abdominal or\n             esophageal discomfort.\n\n          -  Inadequately controlled seizure disorder.\n\n          -  Known intolerance to stavudine, didanosine, and/or hydroxyurea.\n\n          -  Acute and clinically significant medical event within 30 days of screening.\n\n          -  Any clinical or laboratory abnormality greater than Grade 3 toxicity, with the\n             exception of laboratory values given.\n\n        Concurrent Treatment:\n\n        Excluded:\n\n        - Any experimental antiretroviral therapy or immunomodulators directed against HIV-1,\n        e.g., IL-4, cyclosporine steroids at doses greater than 40 mg/day.\n\n        Prior Medication:\n\n        Excluded:\n\n        - Non-nucleoside reverse transcriptase inhibitor therapy.\n\n        Prior Treatment:\n\n        Excluded:\n\n          -  Radiation therapy within 30 days of entry except to a local lesion.\n\n          -  Transfusion of blood or blood products within 21 days of screening.\n\n          -  Cytotoxic therapy within 3 months of study entry.\n\n        Risk Behavior:\n\n        Excluded:\n\n        Active substance abuse that may interfere with compliance or protocol evaluations."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002412", 
            "org_study_id": "292C", 
            "secondary_id": "MKC-305"
        }, 
        "intervention": [
            {
                "intervention_name": "Emivirine", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Hydroxyurea", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Stavudine", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Didanosine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Didanosine", 
                "Stavudine", 
                "Emivirine", 
                "Reverse Transcriptase Inhibitors", 
                "Anti-HIV Agents", 
                "Hydroxyurea", 
                "Protease Inhibitors"
            ]
        }, 
        "keyword": [
            "Didanosine", 
            "Drug Therapy, Combination", 
            "Stavudine", 
            "Hydroxyurea", 
            "Reverse Transcriptase Inhibitors", 
            "Anti-HIV Agents", 
            "Viral Load", 
            "MKC 442"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "St. Petersburg", 
                    "country": "United States", 
                    "state": "Florida", 
                    "zip": "33713"
                }, 
                "name": "Dr Robert Wallace"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Randomized, Double-Blind Study of MKC-442 Combined With Stavudine, Didanosine, and Hydroxyurea in HIV-Infected Patients Who Are Protease Inhibitor Experienced and Non-Nucleoside Reverse Transcriptase Inhibitor Naive", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002412"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Triangle Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 1999"
    }, 
    "geocoordinates": {
        "Dr Robert Wallace": "27.773 -82.64"
    }
}